The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to non-hodgkin lymphoma risk

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Fan, Chuanbo ^a,b   Wei, Jinyu ^d   Yuan, Chenglu ^c   Wang, Xin ^a   Jiang, Chuanwu ^b   Zhou, Changchun ^e   Yang, Ming ^d  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Qingdao Hiser Medical Center   (China)

^c SHANDONG UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^e SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN MDMX; PROTEIN P53;

ADULT; AGE; ALLELE; ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENDER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; MDM4 GENE; NONHODGKIN LYMPHOMA; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK; RISK FACTOR;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84925526055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107047     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Müller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005) Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 84: 1-12.
3. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG (1991) Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338: 1175-1176.
4. Manns A, Hisada M, La Grenade L (1999) Human T-lymphotropic virus type I infection. Lancet 353: 1951-1958.
5. Macsween KF, Crawford DH (2003) Epstein-Barr virus-recent advances. Lancet Infect Dis 3: 131-140.
6. Engels A (2007) Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 16: 401-404.
7. Grulich AE, Vajdic CM (2005) The epidemiology of non-Hodgkin lymphoma. Pathology 37: 409-419.
8. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, et al. (2008) A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40: 1204-1210.
9. Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, et al. (2010) Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 42: 132-136.
10. Skibola CF, Bracci PM, Halperin E, Conde L, Craig DW, et al. (2009) Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet 41: 873-875.
11. Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, et al. (2010) Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 42: 661-664.
12. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
13. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
14. Chen J, Wu X, Lin J, Levine AJ (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445-2452.
15. Landers JE, Cassel SL, George DL (1997) Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57: 3562-3568.
16. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, et al. (1996) MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 15: 5349-5357.
17. Wade M, Wang YV, Wahl GM (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20: 299-309.
18. Linares LK, Hengstermann A, Ciechanover A, Müller S, Scheffner M (2003) HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A 100: 12009-12014.
19. Xiong S, Pant V, Suh YA, Van Pelt CS, Wang Y, et al (2010) Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res 70: 7148-7154.
20. Wynendaele J, Böhnke A, Leucci E, Nielsen SJ, Lambertz I, et al. (2010) An illegitimate microRNA target site within the 39 UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 70: 9641-9649.
21. McEvoy J, Ulyanov A, Brennan R, Wu G, Pounds S, et al. (2012) Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS One 7: e42739.
22. Zhou L, Zhang X, Li Z, Zhou C, Li M, et al. (2013) Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. PLoS One 8: e64331.
23. Liu J, Tang X, Li M, Lu C, Shi J, et al. (2013) Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility. Breast Cancer Res Treat 140: 151-157.
24. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365
25. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, et al. (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38: 1133-1141.
26. Siddique M, Sabapathy K (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500.
27. Ørsted DD, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG (2007) Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 204: 1295-1301.
28. Yang M, Sun T, Zhou Y, Wang L, Liu L, et al. (2012) The functional cytotoxic T lymphocyte-associated Protein 4 49G-to-A genetic variant and risk of pancreatic cancer. Cancer 118: 4681-4686.
29. Chen YD, Zhang X, Qiu XG, Li J, Yuan Q, et al. (2013) Functional FEN1 genetic variants and haplotypes are associated with glioma risk. J Neurooncol 111: 145-151.
30. Kim HN, Yu L, Kim NY, Lee IK, Kim YK, et al. (2010) Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. Am J He-matol 85: 822-824.
31. Havranek O, Spacek M, Hubacek P, Mocikova H, Benesova K, et al. (2011) No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma. Leuk Res 35: 1117-1119.
32. Bittenbring J, Parisot F, Wabo A, Mueller M, Kerschenmeyer L, et al. (2008) MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer 8: 116.
33. Weng Y, Lu L, Yuan G, Guo J, Zhang Z, et al. (2012) p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. PLoS One 7: e45820.
34. Nagpal N, Ahmad HM, Molparia B, Kulshreshtha R (2013) MicroRNA-191, an estrogen-responsive micro RNA, functions as an oncogenic regulator in human breast cancer. Carcinogenesis 34: 1889-1899.